

Analysis of Virulence Genes Among Methicillin Resistant *Staphylococcus aureus* (MRSA) Strains

SeyedeH Mahsan Hoseini Alfatemi¹; Mohammad Motamedifar^{2,*}; Nahal Hadi¹; Hadi Sedigh Ebrahim Saraie¹

¹Department of Bacteriology and Virology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, IR Iran

²Shiraz HIV/Aids Research Center (SHARC), Department of Bacteriology and Virology, Medical School, Shiraz University of Medical science, Shiraz, IR Iran

*Corresponding author: Mohammad Motamedifar, Shiraz HIV/Aids Research Center (SHARC), Department of Bacteriology and Virology, Medical School, Shiraz University of Medical science, Shiraz, IR Iran. Tel: +98-7112304356, Fax: +98-7112304356, E-mail: motamedm@sums.ac.ir

Received: January 1, 2014; Revised: February 17, 2014; Accepted: March 9, 2014

Background: *Staphylococcus aureus* is amongst major human pathogens both in hospitals and the community. This bacterium is an opportunistic pathogen responsible for a large number of self-limiting and even life-threatening diseases in humans. Methicillin resistant *S. aureus* (MRSA) strains are common causes of emerging nosocomial infections and are considered as a major problem for public health.

Objectives: We aimed to study the profile of some virulence genes including: *sea*, *seb*, *sed*, *tst*, *eta*, *etb*, *LukS/F-PV*, *hla* and *hld* in methicillin-resistant *S. aureus* by the PCR technique.

Materials and Methods: A total of 345 isolates of *S. aureus* were collected from clinical specimens of patients referred to teaching hospitals of Shiraz; identification was done by biochemical (catalase, coagulase and DNase) and molecular tests. One hundred and forty six isolates of methicillin-resistant *S. aureus* (MRSA) were obtained and the presence of some toxin genes in these isolates was investigated by the polymerase chain reaction (PCR) technique.

Results: The results showed that among the 345 isolates of *S. aureus*, 148 were confirmed as MRSA by screening with the cefoxitin disc diffusion (30 µg) method. Also among the 148 MRSA isolates, 146 isolates were confirmed as methicillin-resistant by molecular methods. The results showed that the frequency of methicillin-resistant and methicillin-sensitive *S. aureus* isolates during 2012 to 2013 in Namazi and Faghihi hospitals were 146 (42.3%) and 199 (57.7%), respectively. Besides, among the 146 confirmed MRSA isolates, 36.98% (54 isolates) and 63.02% (92 isolates) were related to female and male, respectively. The largest number of cases belonged to sputum samples (58 out of 146). The frequency of the *eta*, *etb*, *sed*, *LukS/F-PV*, *seb*, *tst*, *sea*, *hld* and *hla* genes were 0.68%, 2.05%, 2.05%, 5.47%, 10.95%, 11.64%, 27.39%, 84.24% and 93.15%, respectively. In addition, amongst all examined genes, *hla* (93.15%) and *eta* (0.68%) genes had the highest and lowest frequencies, respectively. The greatest coexistence of genes was observed for the *hla* + *hld* gene combination (48.83%). The results of our study indicate that 98.63% of the isolates were positive for at least one of the virulence genes.

Conclusions: The relative higher frequency of some virulence genes in this study may reflect the emergence of isolates containing these genes in Shiraz medical centers.

Keywords: Methicillin-resistant *Staphylococcus aureus*; Iran

1. Background

Staphylococcus aureus is a Gram-positive bacterium found in axillae, nose, groin, perineal area (males), mucous membranes, mouth, mammary glands, hair, and intestinal, genitourinary and upper respiratory tracts of human and sometimes leads to production of pus and abscesses, sepsis and even fatal septicemia (1-3). *S. aureus* is amongst major human pathogens both in hospitals and the community (4). The bacterium is an opportunistic pathogen that can bring about a multiplicity of self-limiting and even life-threatening diseases in humans (2). Antibiotics such as cephalexin and cloxacillin are usually used to treat staphylococci infections (5). Many strains of *S. aureus* have increased resistance to multiple different

classes of antibiotics (6). Methicillin resistant *S. aureus* (MRSA) strains are common causes of nosocomial infections (7). Increasing resistance to vancomycin, which is administered intravenously and used to treat MRSA, has been documented in many hospitals (6-8).

The universal emerge of MRSA is considered as a major problem for public health (9, 10). The ability of *S. aureus* strains to cause disease depends on a wide range of virulence factors that contribute to colonization and disease in the host (10). *S. aureus* produces an extracellular protein with low molecular weight toxins and virulence factors. Several types of staphylococcal enterotoxins have been reported, including: A, B, C, D, E, F, G, H, I, G, K, L, M,

Implication for health policy/practice/research/medical education:

This study aimed to detect genes involved in the pathogenesis of toxic isolates of methicillin-resistant *Staphylococcus aureus* (MRSA). Besides, the information obtained from the prevalence of toxin genes in MRSA strains can greatly assist health authorities for prevention, control and treatment of related diseases.

Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences; Published by Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

N, O, P, Q and R and their associated genes are: *sea*, *seb*, *sec*, *sed*, *see*, *seg*, *seh*, *sei*, *sej*, *sek*, *sel*, *sem*, *sen*, *seo*, *sep*, *seq* and *ser*, respectively. The enterotoxins are similar to each other in terms of structure and biological activity, but they are different as far as antigen characteristics are concerned (11). More than 90% of staphylococcal enterotoxin food poisonings are related to the A-E groups. The A and D enterotoxins are the major cause of staphylococcal food poisoning (11).

Staphylococcal enterotoxins are heat resistant and if are present in dairy products such as milk and cheese, raw vegetables and candies, they could lead to food poisoning. Staphylococcal enterotoxin poisoning in human causes nausea, vomiting and occasionally leads to diarrhea and muscular and abdominal pain (12). Some *S. aureus* strains produce various types of staphylococcal enterotoxins (SEs), toxic shock syndrome toxin 1 (TSST-1), exfoliative toxins (ETs), hemolysis (alpha, beta, gamma and delta) and Panton Valentine leukocidin (PVL). Toxic shock syndrome toxin 1 and ETS toxins cause toxic shock syndrome and staphylococcal peeling skin syndrome, respectively (13). The alpha, beta, delta, gamma hemolysin and leukocidin toxins are coded by *hla*, *hlb*, *hld*, *hlg* and *lukD-lukE* genes, respectively. These toxins are important in creating a large number of staphylococcal infections (14). Panton Valentine leukocidin toxin has been reported to be associated with severe illnesses in children and adolescents without a prior visit to health care institutions (15).

2. Objectives

In this study, we aimed to investigate the profile of some virulence genes including: *sea*, *seb*, *sed*, *tst*, *eta*, *etb*, *LuKS/F-PV*, *hla* and *hld* in methicillin-resistant *S. aureus* isolates by using the polymerase chain reaction (PCR) technique at two major teaching hospitals in Shiraz, Iran. This study is important for detection of the profile of some virulence genes involved in toxicity of the MRSA pathogenic isolates. Besides, the information obtained from the prevalence of toxin genes in MRSA strains can greatly assist the health authorities for prevention, control and treatment of the related diseases.

3. Materials and Methods

3.1. Bacterial Strains and Culture Media

In this study, bacteria were isolated from patients of two teaching hospitals (Namazi and Faghihi) in Shiraz (Iran) from 2012 to 2013. Samples from various clinical specimens including blood, pus, wound, urine were transferred to the laboratory and subjected to diagnostic tests, such as catalase test, culturing on Mannitol Salt Agar, coagulase tube test and DNase.

3.2. Determination of MRSA Strains and Antibiotic Susceptibility

For differentiation of MRSA from methicillin-sensitive *S. aureus* (MSSA) strains, Muller Hinton Agar medium (Ox-

oid Ltd, UK) was used. The strains in a liquid medium of 0.5 Mc Farland standard concentration were grown in Muller Hinton Agar medium and 30 µg cefoxitin antibiotic discs (Mast Group Ltd, UK) were placed on the medium and incubated for 18 hours at 37°C (16). Next, the diameter of the clear zone around the discs was measured by standards of Clinical Laboratory Standard Institute (CLSI) and the types of MRSA or MSSA strains were identified (Inhibition zone diameter ≤ 21 indicated MRSA and inhibition zone diameter ≥ 22 indicated MSSA) (17).

3.3. DNA Extraction

DNA was extracted using the phenol-chloroform method (18). DNA samples were dissolved in trisacetate-Ethylenediaminetetraacetic acid (Tris-EDTA) buffer (HCl 10 mM Tris, 1 mM EDTA, pH = 7.4), and DNA concentration was determined by spectrophotometer at A260 based on µg/ml concentration. In this study, the quantity of DNA samples used ranged from 10 to 1000 ng. DNA obtained was preserved at -20°C.

3.4. Polymerase chain reaction Assay and Electrophoresis for Detection of Toxin Genes

All MRSA isolates were assayed for the presence of the *sea*, *seb*, *sed*, *tst*, *eta*, *etb*, *LuKS/F-PV*, *hla*, *hld* and *mecA* genes by polymerase chain reaction (PCR) using previously described primers (19, 20) (Table 1). In the present study, the standard strains used for each toxin gene and MRSA are summarized in (Table 2); distilled water was used as the negative control. For PCR, forward and reverse primers (Table 3) were diluted to reach a concentration of 100 pM. After preparing the PCR mix (Tables 4,5), amplifications were performed following programs stated in Table 6. PCR products were mixed with 1 µL of loading buffer solution and carefully loaded in the wells of the agarose gel (1.5%) and electrophoresed at 75 V for 90 minutes. The gel was then stained with ethidium bromide (Merck, Germany) solution for 15 minutes and observed under a UV trans-illuminator.




Figure 1. The Frequency of Isolates Collected From Different Sources of Infection

3.5. Statistical Analysis

For investigating the relationship between data obtained at different stages of this study, data were analyzed in statistical package for social sciences (SPSS) software, version 11.5. Chi-square test was used to determine the relationship between the variables with $P < 0.05$ considered statistically significant.

4. Results

4.1. Biochemical Characterization of Methicillin-Resistant *S. aureus* Isolates

From the samples, various clinical specimens were subjected to diagnostic tests and in total, 345 isolates were

identified as *S. aureus*. Among the 345 isolates of *S. aureus*, 148 were confirmed as MRSA by screening with the cefoxitin disc (30 µg) diffusion method. Using molecular methods, 146 methicillin-resistant isolates were confirmed to have the *mecA* gene using the PCR method, as described earlier. The prevalence rates of MRSA and MSSA isolates were 146 (42.3%) and 199 (57.7%), respectively. From the 146 confirmed isolates, 77 (52.7%) and 69 (47.3%) MRSA belonged to Faghihi hospital and Namazi hospital, respectively. However, the results indicated that the numbers of MRSA isolates obtained from the two hospitals were not significantly different ($P < 0.05$). The rate of MRSA isolation from females and males was 54 (36.98%) and 92 (63.02%), respectively. The frequencies of isolates

Table 1. The Oligonucleotide Sequences and Amplicon Size of Each Gene Used in This Study (19, 20)

	Oligonucleotide Sequence (5'-3')	Amplicon Size, bp
sea		102
GSEAR-1	GGTTATCAATGTGCGGGTGG	
GSEAR-2	CGGCACTTTTTCTCTTCGG	
seb		164
GSEBR-1	GTATGGTGGTGAAGTACGAGC	
GSEBR-2	CCTAATAGTGACGAGTTAGG	
sed		278
GSEDR-1	CCAATAATAGGAGAAAATAAAAG	
GSEDR-2	ATTGGTATTTTTTCGTTTC	
tst		326
GTSSSTR-1	ACCCCTGTTCCTTATCATC	
GTSSSTR-2	TTTTTCAGTATTGTAAACGCC	
eta		93
GETAR-1	GCAGGTGTTGATTTAGCATT	
GETAR-2	AGATGTCCTATTTTTGCTG	
etb		226
GETBR-1	ACAAGCAAAGAATACAGCG	
GETBR-2	GTTTTGGCTGCTTCTCTTG	
LukS/F-PV		443
PVL-1	ATCATTAGGTAATAATGTCTGGACATGATCCA	
NPVL-2	GCATCAAGTGTATTGGATAGCAAAGC	
hla		209
HLA-1	CTGATTACTATCCAAGAAATTCGATTG	
HLA-2	CTTCCAGCCTACTTTTTTATCAGT	
hld		111
HLD-1	AAGAATTTTTATCTTAATTAAGGAAGGAGTG	
HLD-2	TTAGTGAATTTGTTCACTGTGTCGA	
mecA		147
MECA-1	GTGAAGATATACCAAGTGATT	
MECA-2	ATGCGCTATAGATTGAAAGGAT	

Table 2. The Control Strains Used in this Study for Each Toxin Gene of *S. aureus*

Strain Names	Target Genes
<i>S. aureus</i> COL	<i>seb</i>
<i>S. aureus</i> ATCC14458	MRSA, <i>LukS/F-PV</i>
<i>S. aureus</i> N315	<i>hla, hld, eta</i>
<i>S. aureus</i> JCSC/4469	<i>etb, sed, tst, sea</i>

Table 3. The Amount of Injected Water for Dilution of Primers to a Concentration of 100 pM

Primer Name	μL of Water
GSEAR-1	166.03
GSEAR-2	367.59
GSEBR-1	190.23
GSEBR-2	200.96
GSEDR-1	270.46
GSEDR-2	535.28
GTSSIR-1	174.45
GTSSIR-2	346.17
GETAR-1	359.54
GETAR-2	369.59
GETBR-1	192.28
GETBR-2	340.52
PVL-1	155.89
PVL-2	234.71
HLA-1	219.50
HLA-2	181.48
HLD-1	240.84
HLD-2	262.45
MECA-1	304.94
MECA-2	197.89

Table 4. Reagents Used for PCR of All Genes Except for *LukS/F-PV* Gene

Materials	Volume Used, μL	Concentrations
dNTPs (Cinna Gen, Iran)	1	200 μM
MgCl_2 (Merck, Germany)	1.5	1.5 mM
PCR buffer (Cinna Gen, Iran)	2.5	1 X
Forward primer (Cinna Gen, Iran)	1	10 pmol/ μL
Reverse primer (Cinna Gen, Iran)	1	10 pmol/ μL
Taq polymerase (Cinna Gen, Iran)	0.25	1 unit
Double-distilled water (Cinna Gen, Iran)	14.75	-
DNA template	3	-
-	final volume = 25	-

Table 5. Reagents Used for PCR of *LukS/F-PV* Gene

Materials (Co. Name, Country)	Volume Used, μL	Concentration
dNTPs (Cinna Gen, Iran)	1.5	200 μM
MgCl_2 (Merck, Germany)	1	1.5 mM
PCR buffer (Cinna Gen, Iran)	2.5	1 X
Forward primer (Cinna Gen, Iran)	1	10 pmol/ μL
Reverse primer (Cinna Gen, Iran)	1	10 pmol/ μL
Taq polymerase (Cinna Gen, Iran)	0.5	1 unit
Double-distilled water (DDW)	15.5	-
DNA template	2	-
-	final volume = 25	-

Table 6. Thermal Cycler Programs Used in This Study

Cycle Number	Time	Temperature, °C	Definite	Steps	Programs
1	5 min	94	Initial denaturation	1	program 1
30	30 sec	95	Denaturation	1	program 2
30	45 sec	50-60 ^a	Annealing	2	program 2
30	1 min	72	Extension	3	program 2
1	7 min	72	final extension	1	program 3

^a Change in range is inserted suit to different genes. Annealing temperature for the genes were followed as: *eta* and *etb* (54°C); *tst*, *mecA*, *sed* and *seb* (50°C); *LukS/F-PV* and *sea* (60°C); *hla* and *hld* (58°C).

Table 7. Prevalence of Various Genes of MRSA Isolated From Different Specimens

Source	<i>sea</i>	<i>seb</i>	<i>sed</i>	<i>tst</i>	<i>eta</i>	<i>etb</i>	<i>LukS/F-PV</i>	<i>hla</i>	<i>hld</i>
Sputum	13	3	-	3	-	-	-	56	50
Wound	4	6	1	5	-	1	2	17	16
Blood	5	1	-	4	1	1	3	19	18
Nose	3	-	-	1	-	1	-	3	3
Eye	-	-	-	-	-	-	-	3	1
Throat	1	-	-	-	-	-	-	4	2
Urine	5	-	-	-	-	-	-	11	13
Skin	3	4	2	4	-	-	3	8	5
Body fluid	-	-	-	-	-	-	-	3	3
Endotracheal tube	4	1	-	-	-	-	-	5	4
Other	2	1	-	-	-	-	-	7	8
Total, %	27.39	10.95	2.05	11.64	0.68	2.05	5.47	93.15	84.24

collected from different sources of infection are shown in (Figure 1). The results indicated that among the 146 isolates, sputum, blood and urine specimens with 58, 20 and 14 cases, respectively, had the greatest proportions. The results also showed that the nose and eye specimens had the lowest proportion with only three cases (Figure 1).

4.2. Result of Molecular Tests

The results of PCR among methicillin-resistant isolates are shown in Figure 2 and Figure 3, respectively. As shown in Table 7, the frequency of the *sea*, *seb*, *sed*, *tst*, *eta*, *etb*, *LukS/F-PV*, *hla* and *hld* genes were 27.39%, 10.95%, 2.05%, 11.64%, 0.68%, 2.05%, 5.47%, 93.15% and 84.24%, respectively. The highest and lowest frequencies among these genes belonged to *hla* and *eta* genes, respectively. The results showed that the separate frequency of each gene in MRSA isolates from all the cases of Namazi and Faghihi hospitals indicated a significant difference, with $P < 0.05$.

4.3. The Prevalence of Coexistence of Different Genes in MRSA Isolates From Various Specimens


In this study, coexistence of different genes including *sea*, *seb*, *sed*, *tst*, *eta*, *etb*, *LukS/F-PV*, *hla* and *hld* in various specimens of MRSA was investigated. The results of the coexistence prevalence of genes are shown in Table 8. The highest coexistence of different genes belonged to *hla* +

hld genes (48.83%) and the lowest frequency of gene coexistence were related to *hla* + *tst*, *hla* + *hld* + *LukS/F-PV*, *hla* + *hld* + *sed*, *hla* + *seb* + *LukS/F-PV*, *hla* + *sed* + *LukS/F-PV*, *hla* + *hld* + *sea* + *etb*, *hla* + *hld* + *seb* + *LukS/F-PV*, *hla* + *hld* + *sea* + *LukS/F-PV*, *hla* + *hld* + *sed* + *sea*, *hla* + *sea* + *seb* + *tst* and *tst* + *seb* + *sea* + *LukS/F-PV*; where each combination was detected in a single sample (0.68%). Among the 146 isolates, the endotracheal tube and body fluid specimens were devoid of any gene. As indicated in our results, 98.63% of the isolates were positive for at least one of the genes.

5. Discussion


MRSA outbreaks are estimated in about 40-60% of *S. aureus* outbreaks, which are mainly affected by the infection control program and medical treatments leading to a wide range of hospital infections (21). MRSA is the cause of many nosocomial infections in Shiraz. Our study showed that the prevalence of MRSA among *S. aureus* isolates was 42.3%, which indicates little difference in terms of frequency with studies by Fatholahzadeh et al., who reported MRSA prevalence of 36% in Tehran (21). However, MRSA prevalence varies widely between different countries and may reflect the fact that different policies for infection control and other factors are involved in these areas (22). MRSA isolates were identified based on the *mecA* gene and antibiotic sensitivity tests.

Figure 2. Patterns of Agarose Gel Electrophoresis Showing PCR Amplification Products for the Isolated *S. aureus* Genes.



Lanes M, DNA molecular size marker (100-bp ladder; Cinna Gen, Iran); C-: negative control; lane 1: *tst*; lane 2: *LukS/F-PV*; lane 3: *sed*; lane 4: *etb*; lane 5: *seb*; lane 6: *hla*

Figure 3. Patterns of Agarose Gel Electrophoresis Showing PCR Amplification Products for the Isolated *S. aureus* Genes.



Lanes M, DNA molecular size marker (50-bp ladder; Cinna Gen, Iran); C-: negative control; lane 1: *eta*; lane 2: *sea*; lane 3: *hld*

Table 8. Distribution of Toxin Genes Among Methicillin-Resistant *S. aureus* Isolated From Different Specimens^a

Specimens	ET (n=6) ^b	S (n=58)	W (n=18)	B (n=20)	N (n=3)	E (n=3)	T (n=4)	U (n=14)	Sk (n=8)	BF (n=4)	O (n=8)
<i>hla</i>	-	4	-	1	-	2	2	1	-	-	-
<i>hld</i>	-	1	-	1	-	-	-	1	-	-	1
<i>hla + hld</i>	1	35	6	7	-	1	1	7	-	3	5
<i>hla + sea</i>	1	2	-	-	-	-	-	-	-	-	-
<i>hla + tst</i>	-	1	-	-	-	-	-	-	-	-	-
<i>hld + sea</i>	-	1	-	-	-	-	-	2	-	-	-
<i>hla + hld + sea</i>	2	9	1	3	1	-	1	3	-	-	1
<i>hla + hld + seb</i>	-	2	2	-	-	-	-	-	-	-	-
<i>hla + hld + tst</i>	-	2	2	2	-	-	-	-	-	-	-
<i>hla + hld + LukS/F-PV</i>	-	-	-	1	-	-	-	-	-	-	-
<i>hla + hld + eta</i>	-	-	-	1	-	-	-	-	-	-	-
<i>hla + hld + etb</i>	-	-	1	1	-	-	-	-	-	-	-
<i>hla + hld + sed</i>	-	-	1	-	-	-	-	-	-	-	-
<i>hla + seb + LukS/F-PV</i>	-	-	-	-	-	-	-	-	1	-	-
<i>hla + sed + LukS/F-PV</i>	-	-	-	-	-	-	-	-	1	-	-
<i>hla + hld + sea + etb</i>	-	-	-	-	1	-	-	-	-	-	-
<i>hla + hld + seb + LukS/F-PV</i>	-	-	1	-	-	-	-	-	-	-	-
<i>hla + hld + sea + LukS/F-PV</i>	-	-	-	1	-	-	-	-	-	-	-
<i>hla + hld + tst + LukS/F-PV</i>	-	-	-	1	-	-	-	-	1	-	-
<i>hla + hld + sea + seb</i>	1	-	-	-	-	-	-	-	-	-	1
<i>hla + hld + sed + sea</i>	-	-	-	-	-	-	-	-	1	-	-
<i>hla + hld + sea + tst</i>	-	-	1	-	1	-	-	-	1	-	-
<i>hla + sea + seb + tst</i>	-	-	-	1	-	-	-	-	-	-	-
<i>tst + seb + sea + LukS/F-PV</i>	-	-	1	-	-	-	-	-	-	-	-
<i>hla + sea + seb</i>	-	1	1	-	-	-	-	-	1	-	-
<i>hla + hld + seb + tst</i>	-	-	1	-	-	-	-	-	2	-	-

^a Abbreviations: B, blood; BF, body fluid; E, Eye; ET, endotracheal tube; N, nose; O, other; Sk, skin; S, sputum; T, throat; U, Urine; W, Wound.

^b Among ET and BF specimens only in one specimen no toxin genes were present.

This study demonstrated that ceftazidime had a sensitivity of 100% and a specificity of 99% for detecting MRSA isolates but oxacillin had 78% sensitivity and 99% specificity for detection of MRSA isolates (23). Based on the results of many studies, performed to identify MRSA and MSSA isolates, the fact that ceftazidime antibiotic is better than oxacillin antibiotic has been indicated (23-26). The results showed that prevalence of methicillin-resistant *S. aureus* and methicillin-sensitive *S. aureus* isolates during 2012 to 2013 in Namazi and Faghihi Hospitals Shiraz were 42.3% and 57.7%, respectively. Similarly, in 2011 Jimenez et al. studied virulence genes of MSSA and MRSA strains isolated from Children's Hospital, University of Medellin, Colombia. The results of this study showed that the virulence genes in MRSA as compared to MSSA isolates had an increased diversity and repetition (83% vs. 73%) (27). *S. aureus* clinical infection is influenced by the presence of antimicrobial resistance and virulence factors. Acquisition of antibiotic resistance in *S. aureus*, including changes in the secretion of virulence factor expression and resistance in order to survive with reduced expression poison, has been suggested (7). Therefore, in this study we confirmed that diversity and abundance were greater in pathogen carriers of MSSA as compared to MRSA strains. In our study, among the 146 confirmed methicillin-resistant isolates, 54 isolates (36.98%) were females and 92 isolates (63.02%) males. In a study, Rahman et al. in Pakistan reported that among the 929 MRSA isolates, 538 were males and 391 females, respectively (28). Their results are in line with our results regarding the number of isolates from males in comparison to females. Among the 146 samples of MRSA isolated in this study, the highest proportion belonged to sputum samples with a rate of 39.79% (58 patients) whereas eye and nose samples had very low rates of only 2.05% (3 patients). Tanaka et al. reported that among the total specimens collected during 1993-1997 in Japan, most cases of MRSA (34.3%) were obtained from sputum and the least number of specimens were gathered from stool (1.8%) (29). Anagaw et al. in Ethiopia reported that among wound specimens (59.18%), MRSA had the highest isolation frequency (30). According to our studies and various researches from other countries, it can be safely said that the most common MRSA specimens are often associated with sputum and pus. These results directly suggest that MRSA strains are responsible for most respiratory and blood infections (septicemia, endocarditis, etc.) in hospitalized patients (31-33). Also the greater frequency of respiratory specimens indicates more transmission through respiratory tract infections and nosocomial MRSA, as shown by several studies (34, 35). Our results confirm different frequencies of MRSA in various specimens. Many studies have reported that staphylococcal toxins produced are different considering the existence of different genotypes. In addition, it has been suggested that the toxin profiles of *S. aureus* in specific isolates may be affected by

the origins of their geographical location (36, 37).

Several studies have been performed on toxic genes of MRSA to various dimensions, around the world. The frequency of the *sea* gene of MRSA was 58.8% in Gorgan of Iran (38), 33% China (39), 15.78% Canada, (19), 74.4% Tehran of Iran (40), 12% Germany (41), 17.5% Malaysia, (13), 32.07% Tehran of Iran (42), 27% Korea (43), 12% Czech (44) and 30% Turkey (45). In a study carried out in Colombia, among the 30 MRSA isolates, the *nil* gene of *sea* was not reported (27). In a study performed in the United States, the frequency of the *sea* gene was reported in the range of 54-95% (46). The frequency of the *sea* gene in MRSA isolates from various specimens obtained in our study was 27.39%, which is similar to that of the study performed in Korea (43). Moreover, the frequency of the *seb* gene has been investigated by many studies. Frequency of this gene in blood specimens in Gorgan of Iran (38), China (39), Canada (19), Tehran (42), Korea (43), Czech (44), Colombia (26) were 61.3%, 5%, 15.78%, 73.58%, 5.6%, 3%, and 7%, respectively. In our study, the frequency of the *seb* gene was 10.95%. This indicates that different frequencies in Iran in 2012 are somewhat close to the results of related studies from Canada (19).

The frequency rates of *sed* gene in blood specimen studies performed in Tehran (42), Korea (43) and Germany in 1998 (41) and Columbia in 2011 (26) were 3.77%, 2.9%, 2%, and 7%, respectively. The frequency of the *sed* gene in our study was 2.05%. Our results are consistent with those of previous studies and have many similarities. In a study from the United States, 0-13% range for the *sed* gene frequency was reported (46). The frequency of the *tst* gene in various blood and nose specimen studies performed in Germany (41), Tehran (42), Korea (43), Czech (44) and Colombia (24) were 14%, 26.41%, 72.2%, 50% and 2%, respectively. In a study from the United States, 0-78% range for the *tst* gene frequency was reported (46). The frequency of the *tst* gene in our study was 11.64%.

The frequency rates of *eta* gene reported from Germany (41), Czech (44), Turkey, (45), and Colombia (26) were 2%, 10%, 19.2%, and 3%, respectively. In a study from the United States, 0-56% range was reported for the *eta* gene frequency (46). The frequency of the *eta* gene in our study was 0.68%. The frequency of the *etb* gene in studies carried out in Turkey was 9.2% (44). In Colombia, among 30 MRSA, no *etb* gene was detected (26). Moreover, in a study in the United States, 0-22% range was reported for the *etb* gene frequency (46). However, the frequency of the *etb* in our study was 2.05%.

The frequency of *LuKS/F-PV* reported by studies performed in Ahvaz was 7.23% (47), Tehran 24.2% (42), Tehran 19% (39) Isfahan 75% (48) and Colombia 73% (11). In the Czech and Korea, of the specimens studied in 2009 no cases revealed *LuKS/F-PV* gene of MRSA (43, 44). In a study from the United States, 0-100% range for the *LuKS/F-PV* gene frequency was reported (46). The frequency of the *LuKS/F-PV* gene in our study was 5.47%. The frequency obtained in our study is similar to that of a study carried

4. Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C, et al. Immunogenicity of toxins during *Staphylococcus aureus* infection. *Clin Infect Dis*. 2010;**50**(1):61-8.
5. Sharma S, Verma KK. Skin and soft tissue infection. *Indian J Pediatr*. 2001;**68 Suppl 3**:S46-50.
6. Eisenstein BI. Treatment challenges in the management of complicated skin and soft-tissue infections. *Clin Microbiol Infect*. 2008;**14 Suppl 2**:17-25.
7. Collins CH. *Laboratory-acquired infections: history, incidence, causes and prevention*. London: Butterworth & Co (Publishers) Ltd; 1988.
8. Hansra NK, Shinkai K. Cutaneous community-acquired and hospital-acquired methicillin-resistant *Staphylococcus aureus*. *Dermatol Ther*. 2011;**24**(2):263-72.
9. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant *Staphylococcus aureus* as a public-health threat. *Lancet*. 2006;**368**(9538):874-85.
10. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, et al. Is Pantone-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant *Staphylococcus aureus* disease? *J Infect Dis*. 2006;**194**(12):1761-70.
11. Ertas N, Gonulalan Z, Yildirim Y, Kum E. Detection of *Staphylococcus aureus* enterotoxins in sheep cheese and dairy desserts by multiplex PCR technique. *Int J Food Microbiol*. 2010;**142**(1-2):74-7.
12. Akineden O, Hassan AA, Schneider E, Usleber E. Enterotoxigenic properties of *Staphylococcus aureus* isolated from goats' milk cheese. *Int J Food Microbiol*. 2008;**124**(2):211-6.
13. Kim JS, Song W, Kim HS, Cho HC, Lee KM, Choi MS, et al. Association between the methicillin resistance of clinical isolates of *Staphylococcus aureus*, their staphylococcal cassette chromosome mec (SCCmec) subtype classification, and their toxin gene profiles. *Diagn Microbiol Infect Dis*. 2006;**56**(3):289-95.
14. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of *Staphylococcus aureus*. *Clin Microbiol Rev*. 2000;**13**(1):16-34.
15. Holmes A, Ganner M, McGuane S, Pitt TL, Cookson BD, Kearns AM. *Staphylococcus aureus* isolates carrying Pantone-Valentine leukocidin genes in England and Wales: frequency, characterization, and association with clinical disease. *J Clin Microbiol*. 2005;**43**(5):2384-90.
16. Guler L, Ok U, Gunduz K, Gulcu Y, Hadimli HH. Antimicrobial susceptibility and coagulase gene typing of *Staphylococcus aureus* isolated from bovine clinical mastitis cases in Turkey. *J Dairy Sci*. 2005;**88**(9):3149-54.
17. *Performance standard for antimicrobial susceptibility testing*. 12th ed. Englewood, CO, US: Clinical and Laboratory Standard Institute (CLSI); 2010.
18. Sambrook J, Russell DW. Purification of nucleic acids by extraction with phenol: chloroform. *Cold Spring Harb Protoc*. 2006;**2006**(1):4455.
19. Mehrotra M, Wang G, Johnson WM. Multiplex PCR for detection of genes for *Staphylococcus aureus* enterotoxins, exfoliative toxins, toxic shock syndrome toxin 1, and methicillin resistance. *J Clin Microbiol*. 2000;**38**(3):1032-5.
20. Jarraud S, Mougel C, Thioulouse J, Lina G, Meugnier H, Forey F, et al. Relationships between *Staphylococcus aureus* genetic background, virulence factors, agr groups (alleles), and human disease. *Infect Immun*. 2002;**70**(2):631-41.
21. Fatholahzadeh B, Emaneini M, Gilbert G, Udo E, Aligholi M, Modarressi MH, et al. Staphylococcal cassette chromosome mec (SCCmec) analysis and antimicrobial susceptibility patterns of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates in Tehran, Iran. *Microb Drug Resist*. 2008;**14**(3):217-20.
22. Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Methicillin-resistant *Staphylococcus aureus* (MRSA): global epidemiology and harmonisation of typing methods. *Int J Antimicrob Agents*. 2012;**39**(4):273-82.
23. Cremieux AC, Dumitrescu O, Lina G, Vallee C, Cote JF, Muffat-Joly M, et al. Pantone-valentine leukocidin enhances the severity of community-associated methicillin-resistant *Staphylococcus aureus* rabbit osteomyelitis. *PLoS One*. 2009;**4**(9).
24. Skov R, Smyth R, Clausen M, Larsen AR, Frimodt-Moller N, Olsson-Liljequist B, et al. Evaluation of a cefoxitin 30 microg disc on Iso-Sensitest agar for detection of methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother*. 2003;**52**(2):204-7.
25. Felten A, Grandry B, Lagrange PH, Casin I. Evaluation of three techniques for detection of low-level methicillin-resistant *Staphylococcus aureus* (MRSA): a disk diffusion method with cefoxitin and moxalactam, the Vitek 2 system, and the MRSA-screen latex agglutination test. *J Clin Microbiol*. 2002;**40**(8):2766-71.
26. Smyth RW, Kahlmeter G. Mannitol salt agar-cefoxitin combination as a screening medium for methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol*. 2005;**43**(8):3797-9.
27. Jimenez JN, Ocampo AM, Vanegas JM, Rodriguez EA, Garces CG, Patino LA, et al. Characterisation of virulence genes in methicillin susceptible and resistant *Staphylococcus aureus* isolates from a paediatric population in a university hospital of Medellin, Colombia. *Mem Inst Oswaldo Cruz*. 2011;**106**(8):980-5.
28. Rahman S, Mumtaz S, Mufti AJ, Shah SH, Rahman M. Incidence of methicillin resistant *Staphylococcus aureus* in Peshawar. *J Ayub Med Coll Abbottabad*. 2011;**23**(1):99-101.
29. Tanaka Y, Adachi A, Tanaka M. Epidemiological surveys of methicillin-resistant *Staphylococcus aureus* in Tottori Prefecture, Japan. *Yonago Acta Med*. 1999;**42**(3):193-200.
30. Anagaw B, Shiferaw Y, Anagaw B, Biadlegne F, Moges F, Kassu A, et al. Frequency of Methicillin-resistant *Staphylococcus aureus* isolates from Clinical Specimens in Gondar University Hospital, Northwest Ethiopia. *Asia J Med Sci*. 2013;**5**(3):28-33.
31. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. *Curr Opin Infect Dis*. 2009;**22**(4):352-8.
32. Japoni A, Jamalidoust M, Farshad S, Ziyaeyan M, Alborzi A, Japoni S, et al. Characterization of SCCmec types and antibacterial susceptibility patterns of methicillin-resistant *Staphylococcus aureus* in Southern Iran. *Jpn J Infect Dis*. 2011;**64**(1):28-33.
33. Bereket W, Hemalatha K, Getenet B, Wondwossen T, Solomon A, Zeynudin A, et al. Update on bacterial nosocomial infections. *Eur Rev Med Pharmacol Sci*. 2012;**16**(8):1039-44.
34. Kilic A, Li H, Stratton CW, Tang YW. Antimicrobial susceptibility patterns and staphylococcal cassette chromosome mec types of, as well as Pantone-Valentine leukocidin occurrence among, methicillin-resistant *Staphylococcus aureus* isolates from children and adults in middle Tennessee. *J Clin Microbiol*. 2006;**44**(12):4436-40.
35. Kuehnert MJ, Kruszon-Moran D, Hill HA, McQuillan G, McAllister SK, Fosheim G, et al. Prevalence of *Staphylococcus aureus* nasal colonization in the United States, 2001-2002. *J Infect Dis*. 2006;**193**(2):172-9.
36. Moore PC, Lindsay JA. Genetic variation among hospital isolates of methicillin-sensitive *Staphylococcus aureus*: evidence for horizontal transfer of virulence genes. *J Clin Microbiol*. 2001;**39**(8):2760-7.
37. Banks MC, Kamel NS, Zabriskie JB, Larone DH, Ursea D, Posnett DN. *Staphylococcus aureus* express unique superantigens depending on the tissue source. *J Infect Dis*. 2003;**187**(1):77-86.
38. Kamarehei F, Ghaemi EA, Dadgar T. Prevalence of enterotoxin A and B genes in *Staphylococcus aureus* isolated from clinical samples and healthy carriers in Gorgan City, North of Iran. *Indian J Pathol Microbiol*. 2013;**56**(3):265-8.
39. Wang LX, Hu ZD, Hu YM, Tian B, Li J, Wang FX, et al. Molecular analysis and frequency of *Staphylococcus aureus* virulence genes isolated from bloodstream infections in a teaching hospital in Tianjin, China. *Genet Mol Res*. 2013;**12**(1):646-54.
40. Emaneini M, Jabalameli L, Iman-Eini H, Aligholi M, Ghasemi A, Nakhjavani FA, et al. Multiple-locus variable number of tandem repeats fingerprinting (MLVF) and virulence factor analysis of methicillin resistant *Staphylococcus aureus* SCCmec type III. *Pol J Microbiol*. 2011;**60**(4):303-7.
41. Becker K, Roth R, Peters G. Rapid and specific detection of toxigenic *Staphylococcus aureus*: use of two multiplex PCR enzyme immunoassays for amplification and hybridization of staphylococcal enterotoxin genes, exfoliative toxin genes, and toxic shock syndrome toxin 1 gene. *J Clin Microbiol*. 1998;**36**(9):2548-53.
42. Noruzi J, Goudarzi G, Pakzad P, Razavipour R. Isolation and Detection of *Staphylococcus aureus* Enterotoxins A-E and TSST-1 Genes from Different Sources by PCR Method. *J Qom Univer Med Sci*. 2012;**6**(3):78-85.
43. Peck KR, Baek JY, Song JH, Ko KS. Comparison of genotypes and

- enterotoxin genes between *Staphylococcus aureus* isolates from blood and nasal colonizers in a Korean hospital. *J Korean Med Sci*. 2009;**24**(4):585-91.
44. Sila J, Sauer P, Kolar M. Comparison of the prevalence of genes coding for enterotoxins, exfoliatins, panton-valentine leukocidin and *tsst-1* between methicillin-resistant and methicillin-susceptible isolates of *Staphylococcus aureus* at the university hospital in Olomouc. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*. 2009;**153**(3):215-8.
45. Demir C, Aslantas O, Duran N, Ocak S, Ozer B. Investigation of toxin genes in *Staphylococcus aureus* strains isolated in Mustafa Kemal University Hospital. *Turk J Med Sci*. 2011;**41**(2):343-52.
46. Shukla SK, Karow ME, Brady JM, Stemper ME, Kislow J, Moore N, et al. Virulence genes and genotypic associations in nasal carriage, community-associated methicillin-susceptible and methicillin-resistant USA400 *Staphylococcus aureus* isolates. *J Clin Microbiol*. 2010;**48**(10):3582-92.
47. Khosravi AD, Hoveizavi H, Farshadzadeh Z. The prevalence of genes encoding leukocidins in *Staphylococcus aureus* strains resistant and sensitive to methicillin isolated from burn patients in Taleghani hospital, Ahvaz, Iran. *Burns*. 2012;**38**:247-251.
48. Moghadam SO, Havaei SA, Pourmand MR. Prevalence of Methicillin-Resistant *Staphylococcus aureus* Carrying Panton-Valentine Leukocidin Gene in Cutaneous Infections in the City of Isfahan. *J Med Bacteriol*. 2012;**1**(1, 2):9-16.
49. Kateete DP, Namazzi S, Okee M, Okeng A, Baluku H, Musisi NL, et al. High prevalence of methicillin resistant *Staphylococcus aureus* in the surgical units of Mulago hospital in Kampala, Uganda. *BMC Res Notes*. 2011;**4**:326.
50. Novick RP, Schlievert P, Ruzin A. Pathogenicity and resistance islands of staphylococci. *Microbes Infect*. 2001;**3**(7):585-94.
51. Lawrynovicz-Paciorek M, Kochman M, Piekarska K, Grochowska A, Windyga B. The distribution of enterotoxin and enterotoxin-like genes in *Staphylococcus aureus* strains isolated from nasal carriers and food samples. *Int J Food Microbiol*. 2007;**117**(3):319-23.